.. Baxter launches NUMETA emulsion for infusion in Europe Baxter International Inc. announced today the European start of NUMETA . NUMETA was released at the 22nd Annual European Culture of Pediatric and Neonatal Intensive Treatment Medical and Nursing Annual Congress in Hanover, Germany, as the initial and only triple-chamber program with formulations specifically made to meet the selection of intravenous dietary requirements of neonatal and pediatric individuals . This premix therapy addresses a significant unmet medical have to support neonatal and pediatric sufferers’ changing daily nutritional requirements with ready-to-use IV diet. Many preterm infants depend on IV nutrition, also called parenteral diet , at birth to meet up all or component of their daily dietary requirements.Total year 2011 was negatively impacted by a disclosed charge for a legal settlement reserve previously; Free cash flow for the full year was $5.2 billion in comparison to $4.5 billion in 2011; The Company announced that it provides initiated Phase 3 research for AMG 145 in subjects with high levels of low-density lipoprotein cholesterol. ‘We attained strong operating functionality in 2012 as we shipped for sufferers and created worth for shareholders,’ said Robert A. Bradway, chairman and ceo at Amgen. ‘We enter 2013 with good momentum, a broad late-stage pipeline and a continuing concentrate on building our business internationally.’ About Amgen Amgen discovers, develops, manufactures and delivers innovative individual therapeutics.